This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in Predictive Pharmacology and Principal Investigator at the Research Division of Systems Pharmacology and Pharmacy of the Leiden Academic Center for Drug Research (LACDR) discuss the evolution of CNS drug disposition models.
Their discussion highlights the increasing sophistication of physiologically based pharmacokinetic (PBPK) models, including LeiCNS-PK3.0, which outlines how these tools facilitate an improved understanding of CNS drug distribution, better support translational research across species, and more accurately predict human pharmacokinetics.
The discussion also covers a range of other topics, including:
- The scientific needs prompting the development of early CNS drug models
- Current CNS pharmacokinetic models and how these are shaped by microdialysis and PBPK modeling
- The role of the unbound drug concentration (Kpuu) in predicting CNS drug effects
- The use of LeiCNS-PK3.0 and other online models in integrating complex physiological and pharmacodynamic data
- Future research directions and potential translational opportunities in CNS PK/PD modeling
This discussion highlights how decades of collaborative work have driven significant advancements, with work ranging from a seminal 1997 paper on brain drug equilibration to the EU’s QSPainRelief initiative.
Listeners will gain valuable insight into the application of smart data, transporter expression studies, species scaling, and the real-world use of CNS models in reducing clinical failure and predicting patient-specific drug responses.
Acknowledgments
Produced from materials originally authored by Pharmaron Beijing Co., Ltd.
About Pharmaron
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.